AKT1 and non-small cell lung carcinoma: Although the mechanisms of resistance to dabrafenib or dabrafenib-trametinib combination therapy for NSCLC have not been thoroughly described, the activation of the PI3K/AKT/mTOR pathway by PTEN deficiency is considered to be another mechanism.